Dasatinib + quercetin has progressed from preclinical discovery (2015) through multiple human trials (2018–2024) at remarkable speed. Across all trials, the consistent finding is measurable senescent cell burden reduction (via p16, SA-β-Gal, SASP factor biomarkers) and functional improvement proportional to the baseline disease severity.

Which disease has the strongest D+Q evidence?

Physical frailty in older adults has the most statistically significant functional outcome data (gait speed improvement, p=0.0001). The IPF trial, while smaller, has the most direct cellular evidence (biopsy-confirmed senescent cell reduction).

Are the D+Q trial results generalizeable to healthy aging?

All trials enrolled patients with established disease. Extrapolation to healthy individuals suggests benefit (since senescent cells accumulate in all aging organisms) but direct RCT evidence in healthy elderly populations is still pending.